Xtane 25mg Tablet

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Xtane 25mg Tablet can also have adverse effects on the body, most of which resolve without the need for medical attention. In in case of any unusual or severe side effects, immediately.

Some common side effects include:

• Headache
  
• Dizziness
  
• Rash
• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Insomnia (difficulty sleeping)
• Fatigue / Weakness
• Increased sweating
• Hot flushes
• Depression
• Muscle pain / Joint pain / Back pain
• Bone pain / Fracture / Osteoporosis
• Carpal tunnel syndrome (numbness, tingling, hand pain)
• Paresthesia (tingling or pricking sensation)
• Itching (pruritus) / Urticaria
• Hair loss
• Decreased appetite / Increased appetite
• Peripheral edema (swelling in hands and feet)
• Allergic reactions / Difficulty breathing
• Low white blood cell count (lymphocytes, leukopenia)
• Low blood platelets (thrombocytopenia)
• High liver enzyme levels
  

• Doctor determines the exact dose and duration with Xtane 25mg Tablet as per the overall health condition of the patient.
• This tablet should be taken with food or after food, but at the fixed time every day to get effective results.
• Swallow it as a whole with a glass of water and do not crush, chew, or open it.

• Xtane 25mg Tablet is an anticancer medicine with Exemestane as an active ingredient.
• It belongs to the class of drugs known as aromatase inhibitors.
• Exemestane works by blocking the action of the enzyme responsible for the production of the female hormone estrogen to lower its amount in the body.
• It results in controlling the growth of cancer cells as some breast cancer cells require estrogen to multiply.

• Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., ... & Bliss, J. M. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350(11), 1081-1092. https://pubmed.ncbi.nlm.nih.gov/15014181/
• Coleman, R. E., Banks, L. M., Girgis, S. I., Kilburn, L. S., Vrdoljak, E., Fox, J., ... & Coombes, R. C. (2007). Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. The lancet oncology, 8(2), 119-127. https://pubmed.ncbi.nlm.nih.gov/17267326/
• Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., ... & Francis, P. A. (2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. New England Journal of Medicine, 371(2), 107-118. https://pubmed.ncbi.nlm.nih.gov/24881463/
• Deeks, E. D., & Scott, L. J. (2009). Exemestane: a review of its use in postmenopausal women with breast cancer. Drugs, 69(7), 889-918. https://pubmed.ncbi.nlm.nih.gov/19441873/
• Goss, P. E., Ingle, J. N., Alés-Martínez, J. E., Cheung, A. M., Chlebowski, R. T., Wactawski-Wende, J., ... & Richardson, H. (2011). Exemestane for breast-cancer prevention in postmenopausal women. New England Journal of Medicine, 364(25), 2381-2391. https://pubmed.ncbi.nlm.nih.gov/21639806/